Geriatric Medicines Market Forecast, Trend Analysis & Competition Tracking - Global Market Insights 2020 to 2026

Published on : Apr-2020 | List of Tables : 100 | List of Figures : 93 | No. of Pages : 170 | Report Code : FACT4746MR | Format :

Geriatric Population Pool to Broaden Prospects of Geriatric Medicines with Rampant Adoption in North America

There is a substantial uptick in the geriatric population worldwide. The World Health Organization (WHO) concludes that people over the age of 65 constitute the fastest growing segment. By 2050, it is predicted that the global geriatric population shall reach 22%, reaching a figure of 2 billion. It is, therefore, no surprise that incidences of chronic diseases have increased. This increasing geriatric population pool is anticipated to broaden prospects for geriatric medicines in the future.

Increasing government support for the elderly with respect to their health, safety and nursing care has also increased. The prevalence of quality geriatric care management systems is set to expand the global geriatric medicines market. Market estimates project a positive growth trend with a CAGR of 6.0% for the global geriatric medicines market during the forecast period (2020-2026). Technological advancements for medication assistance is also anticipated to leverage the global geriatric medicines market.

Analgesic Therapeutics to Dominate, Antihypertensive Therapeutics to Expand Rapidly

The analgesic therapeutic segment is projected to capture a significant chunk of the global geriatric medicines market. Rising demand for painkillers for various chronic conditions like arthritis is anticipated to boost growth. The analgesic therapeutics segment is projected to grow at a CAGR of 6.0%, capturing over two-fifth of the geriatric medicines market, throughout the forecast period. Major drugs utilized for the geriatric population include Ibuprofen, Diclofenac, Ketorolac and Toradol.

The antihypertensive therapeutics segment is projected to grow the fastest during the forecast period. Rising incidences of hypertension attributed to changing lifestyles and increased life expectancy are poised to leverage prospects for antihypertensive drugs. The drugs in this category include Lotrel and Amlobenz. Anticipated CAGR for antihypertensive therapeutics is pegged at 6.3% during the forecast period.

global geriatric  medicines  market 02

Access our cutting-edge market insights on geriatric medicines market by requesting for a report sample here

Regional Insights: North America to be Market Leader, Asia-Pacific to be Lucrative Pocket

North America shall dominate the global geriatric medicines market. Rise in lifestyle diseases like obesity, well-established healthcare infrastructure, surge in geriatric population and presence of key market players are anticipated to leverage the North American geriatric medicines market. Projections indicate a market share of nearly two-fifths and a CAGR of 5.7% throughout the forecast period. Various clinical studies, research projects and geriatric health management initiatives are underway in North America.

Asia-Pacific is poised to emerge as a lucrative market for geriatric medicines during the forecast period. High economic growth and the resulting increase in disposable incomes, combined with a large population in emerging countries and consequent investment in healthcare infrastructure are anticipated to burgeon market prospects. Over 1/5th of the global geriatric medicines market shall be held by Asia-Pacific. A CAGR of 6.7% is projected for the Asia-Pacific region.

global geriatric  medicines  market 01

For in-depth regional insights on geriatric medicines market, ask an analyst here

New Product Launches and Collaborations to Heighten Key Players’ Market Prospects

The global geriatric medicines market comprises of the following prominent market players: AstraZeneca, Merck & Co, Inc., Pfizer, Inc., Novartis AG, Bristol-Myers Squibb Company, Sanofi S.A., GlaxoSmithKline Plc., Eli Lilly and Company, Abbott Laboratories and Boehringer Ingelheim GmbH. Most of these companies concentrate on establishing a strong market presence through launch of new products, acquisitions & agreements and partnerships with local businesses.

For instance, Pfizer Inc., collaborated with Basilea Pharmaceutica Ltd. for marketing CRESEMBA, an anti-fungal medicine used to treat aspergillosis and mucormycosis in the Asia-Pacific in 2017. Presently, the company manufactures a wide range of products ranging from internal medicines, vaccines, oncology and rare diseases. Some of its medications are Zithromax, Zyvox, Zavicefta, Cresemba, Vfend and Tygacil.

Another important player, Merck & Co., announced in 2017 the launch of RENFLEXIS, a biosimilar of the Remicade medicine, to treat conditions such as Crohn’s Disease, Ulcerative Colitis and Rheumatoid Arthritis. Its existing product portfolio includes drugs such as Invanz for primary care and women’s health, Primaxin for Hospitals & Specialty Clinics and Cancidas for Oncology ailments.

COVID-19 Market Insights:

The ongoing coronavirus pandemic has led to significant disruptions in supply chains across several businesses. Nationwide lockdowns have led to production cuts as manufacturing plants operate at half of their original capacity. It is evident from the statistics that the geriatric population is the most vulnerable to infection from the COVID-19 virus. It is even more dangerous because the elderly already suffer from chronic ailments such as hypertension, diabetes mellitus, renal disorders, cancers, etc. Therefore, geriatric care has registered a significant uptick in the wake of the pandemic.

Prominent market players are effectively responding to the pandemic by streamlining their production processes so that essential medical equipment and drugs are available to healthcare providers to administer to the patients. Astra Zeneca, for instance, is providing COVID-19 testing in the U.K in collaboration with the University of Cambridge and Glaxo Smith Kline since April 2020.

The company has also initiated a new clinical trial to develop a drug that would help alleviate the exaggerated immune response associated with COVID-19 patients. The trial would help assess how one of their existing medicines would help alleviate the cytokine storm associated with the coronavirus disease. Besides its research on COVID-19, the company has also strengthened its production capacities to ensure that geriatric medicines are available to the patients during this crisis.

Analyst’s Viewpoint:

Growing proportion of geriatric population and the resultant prevalence of chronic conditions are expected to significantly heighten growth prospects for the global geriatric medicines market. Further impetus is on the cards in the wake of the coronavirus pandemic.

Global Geriatric Medicines Market: Report Scope:

The recent study by Fact. MR on the global geriatric medicines market incorporates a 6-year forecast on the key drivers, restraints and opportunities for the market. Analysis has been carried out in terms of market share, revenue pool, market attractiveness and growth. The market has been analyzed through various segments, such as therapeutic category, condition and distribution channel.

A separate regional outlook has also been provided in the report. The regional analysis has been conducted across the following five geographies: North America, Europe, Asia-Pacific, Latin America and Middle East & Africa. Each region has incorporated the abovementioned segmental analyses. In addition, a competitive landscape, highlighting key manufacturers’ revenue and market shares, expansion strategies and product launches has been included. A SWOT analysis for each player has also been carried out to provide a realistic picture of the companies’ future business prospects.  

Global Geriatric Medicines Market - Scope of the Report

The recent study by Fact.MR on global geriatric medicines offers a 6-year forecast between 2020 and 2026. The study analyzes crucial trends that are currently determining the growth of the global geriatric medicines market. This report explicates on vital dynamics such as the drivers, restraints and opportunities for key market players along with key stakeholders as well as emerging players associated with the manufacturing of geriatric medicines. The study also provides dynamics that are responsible for influencing the future status of the global geriatric medicines market over the forecast period.

A detailed assessment of the global geriatric medicines market value chain analysis, business execution, and supply chain analysis across the regional markets has been covered in the report. A list of prominent companies operating in the global geriatric medicines market along with their product portfolio enhances the reliability of this comprehensive research study.

Global Geriatric Medicines Market: Report Summary

The study offers a comprehensive analysis on diverse features including production capacities, demand, product developments, revenue generation and sales in global geriatric medicines market across the globe.

A comprehensive estimate of the global geriatric medicines market has been provided through an optimistic as well as a conservative scenario, taking into account the sales of the global geriatric medicines market during the forecast period. Price point comparison by region with global average price is also considered in the study.

Global Geriatric Medicines Market Segmentation

Fact.MR has studied the global geriatric medicines market with detailed segmentation on the basis of therapeutic category, condition, distribution channel and region.

Therapeutic Category

Condition

Distribution Channel

Region

Analgesic

Cardiovascular

Hospital Pharmacies

North America

Anti-hypertensive

Arthritis

Retail Pharmacies

Europe

Statins

Diabetes

Online Pharmacies

Asia Pacific

Anti-diabetic

Neurological

 

Latin America

Proton Pump Inhibitor

Cancer

 

Middle East & Africa (MEA)

Anti-coagulant

Osteoporosis

 

 

Anti-psychotic and Anti-depressant

Respiratory

 

 

 

Others

 

 

“This taxonomy prepared is confidential and intended exclusively for the individual or entity with whom it is being shared. Reading, disseminating, distributing, or copying this to any party other than addressee(s) is unauthorized and prohibited.”

Global Geriatric medicines market: Analysis on Market Size Evaluation

The global geriatric medicines market has been analyzed for each market segment, in terms of value (US$ Mn).

Market estimates at global and regional levels for geriatric medicines market is available in terms of “US$ Mn” for value. A Y-o-Y growth contrast on prominent geriatric medicines market segments, along with market attractiveness evaluation has been incorporated in the report.

Global Geriatric Medicines Market: Inspected Assessment on Regional Segments

Key sections have been elaborated in the global geriatric medicines market report, which have helped to deliver projection on the regional markets. These chapters include the regional macros (economic, and business environment outlook), which are expected to have a momentous influence on the growth of the global geriatric medicines market during the forecast period.

Country-specific valuation on demand for geriatric medicines has been offered for each regional market, along with the market scope, estimate and forecast, price index, and impact analysis of dynamics of prominence in regions and countries. For all regional markets, Y-o-Y growth estimates have also been incorporated in the report.

Detailed breakup in terms of value for emerging countries has also been included in the report.

Global Geriatric Medicines Market: In-Depth Analysis on Competitive Landscape

The report sheds light on the leading manufacturers of global geriatric medicines market along with their detailed profiles. Essential and up-to-date data and information related to the market performers, who are principally engaged in the production of geriatric medicines, has been brought with the help of a detailed dashboard view. Market share analysis and comparison of prominent players provided in the report permits the report readers to take preemptive steps in advancing their businesses.

Company profiles have been included in the report, which includes essentials such as product portfolio, key strategies along with all-inclusive SWOT analysis on each player. Company presence is mapped and presented through the matrix for all the prominent players thus providing the readers with actionable insights, which helps in thoughtfully presenting market status, and predicting the competition level in the global geriatric medicines market. Prominent manufacturers with established market presence in the global geriatric medicines market are AstraZeneca, Merck & Co, Inc., Pfizer, Inc., Novartis AG, Bristol-Myers Squibb Company, Sanofi S.A., GlaxoSmithKline Plc., Eli Lilly and Company, Abbott Laboratories and Boehringer Ingelheim GmbH.

1. Preface

    1.1. Report Scope and Market Segmentation

    1.2. Research Highlights

2. Assumptions and Research Methodology

    2.1. Assumptions and Acronyms Used

    2.2. Research Methodology

3. Executive Summary

    3.1. Global Geriatric Medicines Market Size (US$ Mn) and Forecast, by Region, 2020 and 2026

    3.2. Global Geriatric Medicines Market: Market Snapshot

4. Market Overview

    4.1. Global Geriatric Medicines Market Overview

    4.2. Global Geriatric Medicines Market Key Industry Developments

    4.3. Key Industry Events

5. Market Dynamics

    5.1. Drivers and Restraints Snapshot Analysis

    5.2. Drivers

    5.3. Restraints

    5.4. Opportunities

    5.5. Key Trends

    5.6. Global Geriatric Medicines Market Revenue Projections (US$ Mn), 2020–2026

    5.7. Geriatric Medicines Market: Mergers & Acquisitions

    5.8. Regulatory Framework

    5.9. Heat Map Analysis - Company

6. Global Geriatric Medicines Market Analysis, by Therapeutic Category

    6.1. Introduction

    6.2. Key Insights

    6.3. Global Geriatric Medicines Market Size and Forecast, by Therapeutic Category

        6.3.1. Analgesic

        6.3.2. Antihypertensive

        6.3.3. Statins

        6.3.4. Antidiabetic

        6.3.5. Proton Pump Inhibitor

        6.3.6. Anticoagulant

        6.3.7. Antipsychotic and Antidepressant 

        6.3.8. Others 

    6.4. Global Geriatric Medicines Market Analysis, by Therapeutic Category

    6.5. Global Geriatric Medicines Market Attractiveness Analysis, by Therapeutic Category

7. Global Geriatric Medicines Market Analysis, by Condition

    7.1. Introduction

    7.2. Key Insights

    7.3. Global Geriatric Medicines Market Size and Forecast, by Condition

        7.3.1. Cardiovascular

        7.3.2. Arthritis

        7.3.3. Diabetes

        7.3.4. Neurological

        7.3.5. Cancer

        7.3.6. Osteoporosis 

        7.3.7. Respiratory

        7.3.8. Others

    7.4. Global Geriatric Medicines Market Analysis, by Condition

    7.5. Global Geriatric Medicines Market Attractiveness Analysis, by Condition

8. Global Geriatric Medicines Market Analysis, by Distribution Channel

    8.1. Introduction

    8.2. Key Insights

    8.3. Global Geriatric Medicines Market Size and Forecast, by Distribution Channel

        8.3.1. Hospital Pharmacies

        8.3.2. Retail Pharmacies

        8.3.3. Online Pharmacies

    8.4. Global Geriatric Medicines Market Analysis, by Distribution Channel

    8.5. Global Geriatric Medicines Market Attractiveness Analysis, by Distribution Channel

9. Global Geriatric Medicines Market Analysis, by Region

    9.1. Introduction

    9.2. Key Insights

    9.3. Global Geriatric Medicines Market Size and Forecast , by Region, 2020–2026

        9.3.1. North America

        9.3.2. Europe

        9.3.3. Asia Pacific

        9.3.4. Latin America

        9.3.5. Middle East & Africa

    9.4. Global Geriatric Medicines Market Analysis, by Region

    9.5. Global Geriatric Medicines Market Attractiveness Analysis, by Region

10. North America Geriatric Medicines Market Analysis

    10.1. North America Geriatric Medicines Market Key Findings

    10.2. North America Geriatric Medicines Market Overview

    10.3. North America Geriatric Medicines Market Size and Forecast, by Therapeutic Category

        10.3.1. Analgesic

        10.3.2. Antihypertensive

        10.3.3. Statins

        10.3.4. Antidiabetic

        10.3.5. Proton Pump Inhibitor

        10.3.6. Anticoagulant

        10.3.7. Antipsychotic and Antidepressant 

        10.3.8. Others

        10.3.9. North America Geriatric Medicines Market Analysis, by Therapeutic Category

    10.4. North America Geriatric Medicines Market Size and Forecast, by Condition

        10.4.1. Cardiovascular

        10.4.2. Arthritis

        10.4.3. Diabetes

        10.4.4. Neurological

        10.4.5. Cancer

        10.4.6. Osteoporosis 

        10.4.7. Respiratory

        10.4.8. Others

    10.5. North America Geriatric Medicines Market Forecast, by Distribution Channel

        10.5.1. Hospital Pharmacies

        10.5.2. Retail Pharmacies

        10.5.3. Online Pharmacies

    10.6. North America Geriatric Medicines Market Forecast, by Country

        10.6.1. U.S.

        10.6.2. Canada

    10.7. North America Geriatric Medicines Market Attractiveness Analysis 

        10.7.1. By Therapeutic Category

        10.7.2. By Condition

        10.7.3. By Distribution Channel

        10.7.4. By Country

11. Europe Geriatric Medicines Market Analysis

    11.1. Europe Geriatric Medicines Market Key Findings

    11.2. Europe Geriatric Medicines Market Overview

    11.3. Europe Geriatric Medicines Market Size and Forecast, by Therapeutic Category

        11.3.1. Analgesic

        11.3.2. Antihypertensive

        11.3.3. Statins

        11.3.4. Antidiabetic

        11.3.5. Proton Pump Inhibitor

        11.3.6. Anticoagulant

        11.3.7. Antipsychotic and Antidepressant 

        11.3.8. Others

    11.4. Europe Geriatric Medicines Market Size and Forecast, by Condition

        11.4.1. Cardiovascular

        11.4.2. Arthritis

        11.4.3. Diabetes

        11.4.4. Neurological

        11.4.5. Cancer

        11.4.6. Osteoporosis 

        11.4.7. Respiratory

        11.4.8. Others

    11.5. Europe Geriatric Medicines Market Forecast, by Distribution Channel

        11.5.1. Hospital Pharmacies

        11.5.2. Retail Pharmacies

        11.5.3. Online Pharmacies

    11.6. Europe Geriatric Medicines Market Forecast, by Country

        11.6.1. Germany

        11.6.2. U.K.

        11.6.3. France

        11.6.4. Spain

        11.6.5. Italy

        11.6.6. Rest of Europe

    11.7. Europe Geriatric Medicines Market Attractiveness Analysis

        11.7.1. By Therapeutic Category

        11.7.2. By Condition

        11.7.3. By Distribution Channel

        11.7.4. By Country

12. Asia Pacific Geriatric Medicines Market Analysis

    12.1. Asia Pacific Geriatric Medicines Market Key Findings

    12.2. Asia Pacific Geriatric Medicines Market Overview

    12.3. Asia Pacific Cytometry Market Size and Forecast, by Therapeutic Category

        12.3.1. Analgesic

        12.3.2. Antihypertensive

        12.3.3. Statins

        12.3.4. Antidiabetic

        12.3.5. Proton Pump Inhibitor

        12.3.6. Anticoagulant

        12.3.7. Antipsychotic and Antidepressant 

        12.3.8. Others

    12.4. Asia Pacific Geriatric Medicines Market Size and Forecast, by Condition

        12.4.1. Cardiovascular

        12.4.2. Arthritis

        12.4.3. Diabetes

        12.4.4. Neurological

        12.4.5. Cancer

        12.4.6. Osteoporosis 

        12.4.7. Respiratory

        12.4.8. Others

    12.5. Asia Pacific Geriatric Medicines Market Forecast, by Distribution Channel

        12.5.1. Hospital Pharmacies

        12.5.2. Retail Pharmacies

        12.5.3. Online Pharmacies

    12.6. Asia Pacific Geriatric Medicines Market Forecast, by Country

        12.6.1. China

        12.6.2. India

        12.6.3. Japan

        12.6.4. Australia & New Zealand

        12.6.5. Rest of Asia Pacific

    12.7. Asia Pacific Geriatric Medicines Market Attractiveness Analysis 

        12.7.1. By Therapeutic Category

        12.7.2. By Condition

        12.7.3. By Distribution Channel

        12.7.4. By Country

13. Latin America Geriatric Medicines Market Analysis

    13.1. Latin America Geriatric Medicines Market Key Findings

    13.2. Latin America Geriatric Medicines Market Overview

    13.3. Latin America Cytometry Market Size and Forecast, by Therapeutic Category

        13.3.1. Analgesic

        13.3.2. Antihypertensive

        13.3.3. Statins

        13.3.4. Antidiabetic

        13.3.5. Proton Pump Inhibitor

        13.3.6. Anticoagulant

        13.3.7. Antipsychotic and Antidepressant 

        13.3.8. Others

    13.4. Latin America Geriatric Medicines Market Size and Forecast, by Condition

        13.4.1. Cardiovascular

        13.4.2. Arthritis

        13.4.3. Diabetes

        13.4.4. Neurological

        13.4.5. Cancer

        13.4.6. Osteoporosis 

        13.4.7. Respiratory

        13.4.8. Others

    13.5. Latin America Geriatric Medicines Market Forecast, by Country

        13.5.1. Brazil

        13.5.2. Mexico

        13.5.3. Rest of Latin America

    13.6. Latin America Geriatric Medicines Market Forecast, by Distribution Channel

        13.6.1. Hospital Pharmacies

        13.6.2. Retail Pharmacies

        13.6.3. Online Pharmacies

    13.7. Latin America Geriatric Medicines Market Attractiveness Analysis

        13.7.1. By Therapeutic Category

        13.7.2. By Condition

        13.7.3. By Distribution Channel

        13.7.4. By Country

14. Middle East & Africa Geriatric Medicines Market Analysis

    14.1. Middle East & Africa Geriatric Medicines Market Key Findings

    14.2. Middle East & Africa Geriatric Medicines Market Overview

    14.3. Middle East & Africa Cytometry Market Size and Forecast, by Therapeutic Category

        14.3.1. Analgesic

        14.3.2. Antihypertensive

        14.3.3. Statins

        14.3.4. Antidiabetic

        14.3.5. Proton Pump Inhibitor

        14.3.6. Anticoagulant

        14.3.7. Antipsychotic and Antidepressant 

        14.3.8. Others

    14.4. Middle East & Africa Geriatric Medicines Market Size and Forecast, by Condition

        14.4.1. Cardiovascular

        14.4.2. Arthritis

        14.4.3. Diabetes

        14.4.4. Neurological

        14.4.5. Cancer

        14.4.6. Osteoporosis 

        14.4.7. Respiratory

        14.4.8. Others

    14.5. Middle East & Africa Geriatric Medicines Market Forecast, by Distribution Channel

        14.5.1. Hospital Pharmacies

        14.5.2. Retail Pharmacies

        14.5.3. Online Pharmacies

    14.6. Middle East & Africa Geriatric Medicines Market Size and Forecast, by Country

        14.6.1. GCC Countries

        14.6.2. Israel

        14.6.3. South Africa

        14.6.4. Rest of Middle East & Africa

    14.7. Middle East Geriatric Medicines Market Attractiveness Analysis

        14.7.1. By Therapeutic Category

        14.7.2. By Condition

        14.7.3. By Distribution Channel

        14.7.4. By Country

15. Competition Landscape

    15.1. Global Geriatric Medicines Market Share Analysis, by Company (2018)

    15.2. Company Profiles

        15.2.1. Pfizer, Inc.

            15.2.1.1. Overview (HQ, Employee Strength, Business Segments)

            15.2.1.2. Financials

            15.2.1.3. Recent Developments

            15.2.1.4. Strategy

        15.2.2. Merck & Co., Inc.

            15.2.2.1. Overview (HQ, Employee Strength, Business Segments)

            15.2.2.2. Financials

            15.2.2.3. Recent Developments

            15.2.2.4. Strategy

        15.2.3. AstraZeneca

            15.2.3.1. Overview (HQ, Employee Strength, Business Segments)

            15.2.3.2. Financials

            15.2.3.3. Recent Developments

            15.2.3.4. Strategy

        15.2.4. Bristol-Myers Squibb Company

            15.2.4.1. Overview (HQ, Employee Strength, Business Segments)

            15.2.4.2. Financials

            15.2.4.3. Recent Developments

            15.2.4.4. Strategy

        15.2.5. Novartis AG

            15.2.5.1. Overview (HQ, Employee Strength, Business Segments)

            15.2.5.2. Financials

            15.2.5.3. Recent Developments

            15.2.5.4. Strategy

        15.2.6. Sanofi S.A.

            15.2.6.1. Overview (HQ, Employee Strength, Business Segments)

            15.2.6.2. Financials

            15.2.6.3. Recent Developments

            15.2.6.4. Strategy

        15.2.7. GlaxoSmithKline plc

            15.2.7.1. Overview (HQ, Employee Strength, Business Segments)

            15.2.7.2. Financials

            15.2.7.3. Recent Developments

            15.2.7.4. Strategy

        15.2.8. Eli Lilly and Company

            15.2.8.1. Overview (HQ, Employee Strength, Business Segments)

            15.2.8.2. Financials

            15.2.8.3. Recent Developments

            15.2.8.4. Strategy

        15.2.9. Abbott Laboratories

            15.2.9.1. Overview (HQ, Employee Strength, Business Segments)

            15.2.9.2. Financials

            15.2.9.3. Recent Developments

            15.2.9.4. Strategy

        15.2.10. Boehringer Ingelheim GmbH

            15.2.10.1. Overview (HQ, Employee Strength, Business Segments)

            15.2.10.2. Financials

            15.2.10.3. Recent Developments

            15.2.10.4. Strategy

Fact.MR offers custom research services that help clients to get specific research solutions

We are committed towards customer satisfaction and quality service.


Our Clients

Malaysian Cocoa Board
Dunlop International Europe Ltd
Roland Berger
Superior Essex
Commscope
Deloitte

Fact.MR in Media

Geriatric Medicines Market Forecast, Trend Analysis & Competition Tracking - Global Market Insights 2020 to 2026